The administration of didanosine (ddI) in the adult: a nursing perspective.
Until October 1991, zidovudine was the only licensed anti-HIV drug. Because zidovudine has limitations, the development of additional drugs is needed. One such drug is didanosine, which received FDA approval for patients who are intolerant of zidovudine or who have received prolonged zidovudine therapy. The authors provide an overview of the administration and adverse effects of didanosine, and recommend nursing interventions.
Vaccariello
J
J
AIDS Clinical Trials Unit, New York University Medical Center, New York City.
Funesti
J C
JC
Laverty
M K
MK
Vasquez
M
M
Curran-Krikorian
K
K
D000328:Adult; D001682:Biological Availability; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000451:nursing; D006801:Humans; D009730:Nursing Assessment; D009737:Nursing Records; D010347:Patient Care Planning
D016049:Didanosine